Introduction
============

Chronic autoimmune inflammatory diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and Crohn's disease, are progressive conditions associated with disability, morbidity, and mortality.[@b1-ppa-4-379] The introduction of injectable disease-modifying drugs a decade ago has had a considerable impact on the progression of such diseases, arresting joint deformities in RA and disease exacerbation in MS for extended periods.[@b2-ppa-4-379] Consequently, patients' adherence to treatment has become a major requisite for achieving optimal treatment efficacy and expected therapeutic outcome.[@b3-ppa-4-379] Factors that influence compliance with injectable treatment in RA remain underinvestigated, while more of these newer injectable biologics are becoming available for use.[@b4-ppa-4-379] recent report has suggested that for chronic injectable treatment, self-injection is associated with better compliance than injection by a family member or by a health care professional.[@b4-ppa-4-379]

A self-administered injectable drug should provide patients with a better quality of life due to the increased autonomy and flexibility in adhering to the treatment regimen. Ready-to-use, disposable autoinjectors, prefilled with a fixed drug dose, are currently under clinical development.

This article reports the results of a clinical trial evaluating the performance, safety, and subject acceptability of a newly developed, disposable autoinjector for subcutaneous (SC) injection, which has been specifically designed to improve adherence to an injection schedule. The primary study objective was to evaluate the performance of the prefilled autoinjector used by the subjects relative to standard SC injection by nurses using a prefilled syringe. Secondary objectives were to assess the subjects' pain during the injection, skin reaction, and their compliance with the instructions for use (IFU). Finally, subject preference for self-injection or for injection by a nurse was investigated.

Material and methods
====================

Study design
------------

This study was a randomized, single-center, crossover study comparing self-injection with injection by nurses in healthy volunteers. The study was conducted in France after approval by the Ethics Committee, and in compliance with the latest revision of the Declaration of Helsinki, and with Good Clinical Practice according to European directives and French laws. Each subject came for three separate sessions of eight injections. The order of injections was balanced across all subjects in terms of the system, volume, and injection site, and subjects were randomly assigned to a prespecified order of injection (see [Figure 1](#f1-ppa-4-379){ref-type="fig"}). An independent observer watched each injection and reported noncompliance with the injection procedure according to a pre-established list of items, including subject errors when handling the autoinjector and performing the injection.

Subjects
--------

Subject selection and recruitment, and the clinical phase of the study were conducted by a French investigation center (Eurofins Optimed, Grenoble, France). The required number of subjects was 40. The main eligibility criteria were the following: healthy men and women aged 25--35 years or 45--65 years, free of drugs having an impact on pain perception during the clinical investigations (last drug intake at least six elimination half-lives before injection), without previous experience of self-injection or giving injections, and without current visible skin disease at the targeted injection sites. The group aged 25--35 years was selected to correspond with the age of onset of MS, while subjects in the group aged 45--65 years represented those in the RA population. Subject selection was based on reported clinical history, physical examination, blood tests, absence of ongoing chronic disease, and concomitant treatment.

Injection system and injection procedures
-----------------------------------------

The standard injection system used by the nurses was a 1 mL sterile, single-use, prefilled glass syringe (BD Hypak™; BD, Franklin Lakes, NJ), and the investigational system was the newly developed, prefilled, ready-to-use, single-use autoinjector used by the subject for self-injection (BD Physioject™). The prefilled BD Hypak syringe and the prefilled syringe assembled inside the autoinjector were the same, with a preattached needle (27 gauge, 12.7 mm). Syringes were prefilled with sterile, pyrogen-free, saline (0.9% sodium chloride) solution. The two injection volumes evaluated (0.2 mL and 1 mL) correspond to the minimum and maximum volumes targeted to be injected with the BD Physioject disposable autoinjector. Prior to the study, all subjects were individually trained to perform SC injections into a skin-fold using the autoinjector. The IFU comprised 10 steps. To counteract any variability between health care professionals on the subjects' cognitive perception of the injection, 14 nurses performed the injections with prefilled syringes, and each subject had a different nurse at each of the three sessions. Nurses performed SC injections according to their usual technique with a skin-fold.

Assessments
-----------

The accuracy and consistency of the injected volume was evaluated by gravimetric methodology using a 0.01 mg precision balance (Sartorius BD211D™ E2 precision class).[@b5-ppa-4-379] The injection system weight was recorded before and after each injection, and the fluid leakage volume was assessed by collecting the fluid on the skin surface at the injection site immediately after completion of the injection, using ophthalmic sponges. The injected volume was calculated based on the weight of the injection systems before and after injection, and the weight of the sponges before and after leakage collection.

Fluid injection into the hypodermis changes the local ultrasound echostructure of the tissue. Therefore, the injected fluid depot in the hypodermis layer was determined immediately after injection completion using ultrasound sonography (Logiq 500™, 11 MHz two-dimensional probe, in mode B; GE Medical Systems, Chalfont St Giles, UK). The fluid depot location in the body tissue layers was determined by measuring the distance (in mm) between the skin surface and the bottom of the fluid depot. This noninvasive method increased the duration of the subjects' sessions in the clinical center. Because this was an exploratory objective, it was considered sufficient to perform ultrasound assessment on a full set of eight injections from one session only, for all subjects.

Subjects' pain during the injection was measured using a 100 mm visual analog scale (VAS) ranging from "no pain" to "very painful", and a verbal scale with a choice of eight answers ranging from "I did not perceive anything" to "I perceived an intense pain".[@b6-ppa-4-379],[@b7-ppa-4-379] double measurement in millimeters (VAS and verbal scale) was performed by two clinical trial technicians. Subjects completed one VAS and one verbal scale immediately after each injection. Local skin reaction was scored after visual inspection of the injection site, recording redness (erythema), bleeding, bruising, edema, and itching. These criteria were used to determine each subject's acceptance of the treatment.[@b7-ppa-4-379]

The overall subject preference regarding self-injection compared with injection by a nurse was evaluated using specifically designed questionnaires assessing a subject's emotions and attitudes.[@b8-ppa-4-379]--[@b10-ppa-4-379] Evaluations were made before initiating the investigation and after each session. At the end of the last injection session, subjects were asked to choose between self-injection and injections by nurses for an additional unscheduled injection. In addition, they were asked which combination of systems they would prefer should they ever need a chronic treatment administered by SC injection, ie, a nurse giving the injection using a syringe or an autoinjector, or performing self-injection themselves using a syringe or an autoinjector.

Data analysis
-------------

Data were analyzed using the SAS^®^ computer program (version 8.2; SAS Institute, Cary, NC). With regard to the primary objective, a 95% confidence limit for the 95th percentile of the "fluid leakage" population was calculated per system and per injection volume. The 95% upper confidence limit was compared with 10 μL for the 0.2 mL injection volume, and with 50 μL for the 1 mL injection volume. A repeated-measures mixed model with subjects as random effects, device, gender, session, and site as fixed effects, and age as a covariable was used to compare performance (average fluid leakage volume and injected volume), average pain, and average fluid depot depth between the two systems per body site and per injection volume. In the presence of non normality, analysis was performed after a normalizing transformation of the data. Skin reactions were analyzed using ordinal logistic regression (edema and bleeding), or Fisher's exact test when the number of positive observations was small (itching, bruising, and erythema). Data on compliance with self-injection IFU were analyzed using a mixed model, whereas data on preference, emotions, and attitudes were analyzed using comparative *t*-tests and, where relevant, analysis of variance.

Skin reactivity and acceptance were analyzed on the safety set corresponding to all injections of all subjects randomized who had at least one injection, including subjects prematurely withdrawn. The per protocol (PP) set corresponded to the safety set with no major protocol deviation. Injection system performance (except for ultrasound assessment) and subject pain were analyzed on the PP set, taking into account all injections (24 per subject, 40 subjects, ie, 960 injections). Ultrasound assessment was analyzed on the restricted subset of eight injections per subject in the PP set (ie, 320 injections). Compliance with self-injection IFU was analyzed on the PP set, taking into account all self-injections (ie, 480 injections with the autoinjector). Subject preference was analyzed on the PP set, taking into account the opinion of each subject (ie, 40 subjects' answers).

Results
=======

Analysis of population
----------------------

Of the 62 subjects screened, a total of 40 healthy volunteers were enrolled, as described in [Table 1](#t1-ppa-4-379){ref-type="table"}. All 960 planned injections were performed and analyzed. Due to the absence of premature withdrawal, the safety set and PP populations were the same, and had an effective of 960 injections (480 with syringes, 480 with autoinjectors).

Injection system performance
----------------------------

The data summary results on fluid leakage and injected volume are reported in [Table 2](#t2-ppa-4-379){ref-type="table"}. Fluid leakage was not collected for 88 injections, mostly because of blood droplets at the injection site. The mixed-model analysis indicated no significant effect of testing factors on leakage volume and injected volume. The only exception to this was gender, but this effect was not clinically significant, ie, leakage volume was higher in female (2.7 μL) than in male subjects (1.6 μL, *P* = 0.0003), and injected volume was higher in male (0.207 and 1.014 mL) than in female subjects (0.206 and 1.011 mL, respectively, *P* = 0.0037). The rate of injected volume below the expected injected volume was six of 480 injections with the autoinjector (five and one injections for 0.2 mL and 1 mL, respectively) compared with 17 of 480 with the syringes (eight and nine injections for 0.2 mL and 1 mL, respectively). Whatever the injected volume, the estimate of the 95th percentile of leakage volume and its 95% confidence interval (CI) were below the threshold of 5% of injection volume. These results indicate that the accuracy and consistency of the volume injected by self-injection are not significantly different from injections given by nurses.

In total, 320 ultrasound assessments were performed, comprising 160 after injections by a nurse and 160 after self-injections. For one injection, delivering a fluid volume of 1 mL by autoinjector, no fluid depot was detected on ultrasound examination. Fluid depot location in the hypodermis after injection was detected using ultrasound sonography for 159 injections across 160 analyzed injection sites. [Figure 2](#f2-ppa-4-379){ref-type="fig"} presents a box plot (arithmetic mean, median, and minimum and maximum values) of depth of the injection fluid depot from the skin surface. The mixed-model analysis indicated no significant difference in depth of the fluid depot between the two groups. No effect of body site or of injected volume was detected.

Subject pain, skin reaction, and acceptance
-------------------------------------------

Pain measured by a VAS immediately after each of the 960 injections is reported in [Figure 3](#f3-ppa-4-379){ref-type="fig"} and [Table 3](#t3-ppa-4-379){ref-type="table"}. Subjects reported significantly less pain when injections were self-administered by the autoinjector than when given by nurses with the syringe (*P* \< 0.0001), and with an injection of 0.2 mL rather than 1.0 mL (*P* = 0.0003). Female subjects reported less pain than male subjects (*P* \< 0.0001). Similar significant differences were also recorded using the verbal scale, except for the gender effect. As detailed below regarding subject acceptance, the reduction in pain was associated with a preference for self-injection.

Skin reactions at the injection site immediately after each of the 960 injections are reported in [Table 4](#t4-ppa-4-379){ref-type="table"}. The most frequent local reaction was bleeding, seen mostly as a spot of blood corresponding to needle penetration through the skin. This very minor local bleeding was recorded more frequently with self-injections than with syringes (43.1% versus 10.6%, respectively). Local edema was observed in a few cases and was more frequent with injections by nurses.

A total of 15 adverse events occurred following the 960 injections (15/960, 1.6%), all of which were of mild intensity and resolved spontaneously by the end of the study. The only systemic adverse event was vague malaise after manual injection by a nurse. Most adverse events comprised delayed hematoma in 14/960 cases (1.4%) at the injection site. The autoinjector was responsible for six cases of delayed hematoma and the syringe was responsible for two cases; identification of the causative injection system was not possible in six of 14 cases due to the delay in onset.

Compliance with self-injection instructions for use
---------------------------------------------------

Based on the observation by a nurse of the 480 injections performed by the subjects with the autoinjector, the mean percentage of steps performed in compliance with IFU was 92.9% (95% CI: 92.3%--93.6%). An age effect was detected, with greater compliance among younger subjects (93.6% in the group aged 25--35 years versus 92.0% in the group aged 45--65 years, *P* = 0.0163), but this is not clinically relevant.

Subject preference for self-injection, emotions, and attitudes
--------------------------------------------------------------

The 40 subjects completed a questionnaire about their emotions, attitudes, and preference. Subjects' emotions regarding self-injection were reflected in words such as "pleasant", "comforting", "reassuring", and "less anxious" (14/40, 35%). Ease of use (10/40, 25%) and the autonomy associated with self-injection (8/40, 20%) were also deemed important.

A majority of subjects reported positive attitudes and emotions with self-injection. However, statistical analysis showed that injection by a nurse was perceived as "easier", "reliable", and more "reassuring" compared with self-injection.

When subjects were asked which injection system they would prefer for an additional unforeseen injection, all subjects selected self-injection. In the event that they ever needed chronic treatment administered by SC injection, subjects ranked self-injection with the autoinjector first ([Figure 4](#f4-ppa-4-379){ref-type="fig"}).

Discussion
==========

This study is the first clinical trial in humans evaluating the newly developed autoinjector BD Physioject. Because the main objectives were to document the intrinsic performance, safety, and subject acceptance of the injection system, the trial was conducted in healthy volunteers using a placebo solution. The demographic characteristics of the enrolled subjects were well matched to those reported for MS and RA populations.[@b11-ppa-4-379],[@b12-ppa-4-379]

Ultrasound is an accurate method of measuring depth of the fluid depot in SC tissue. It has been used in previous studies at similar injection sites, and in subjects of similar age and gender to those participating in this study. We used a two-dimensional ultrasound method with an 11 MHz probe. The reliability of this imaging technology was confirmed by two previous studies using two-dimensional ultrasound assessment to detect, respectively, 0.1 mL and 0.5 mL injections of saline solution in SC tissue, with a 5 MHz and a 16 MHz probe, respectively.[@b13-ppa-4-379],[@b14-ppa-4-379]

Performance and variability in injected volume accuracy with self-injections were not significantly different from those associated with injections given by nurses. Indeed, regardless of the system, fluid leakages were in the range of a few microliters for a total injected volume of 0.2 mL or 1 mL. Of note, the volume per injection of most of the drugs approved or in clinical development for autoimmune inflammatory diseases is at least 0.5 mL. In the present study, the rate of injected volume below the expected injected volume was six of 480 injections with the autoinjector compared with 17 of 480 with the syringes.

The injected fluid depot in the hypodermis was observed in 98.8% of SC self-injections and 100% of injections administered by nurses. Subjects were asked to make a skin-fold, which was not obvious to healthy subjects who are naïve to injection practice, and resulted in skin-folds that were highly variable in size and quality. Skin-folds made by nurses were more alike. One injection fluid depot by self-injection was detected at a depth of 6.6 mm from the skin surface, most likely because the subject had a very low body mass index (18.3 kg/m^2^). Another injection fluid depot was at a depth of 3.3 mm, and categorized as located in the shallow hypodermis. Studies evaluating SC skin thickness using ultrasound evaluation have reported a mean abdomen SC skin thickness ranging from 12.2 mm to 40.2 mm according to gender and body mass index,[@b14-ppa-4-379],[@b15-ppa-4-379] and a mean anterior thigh SC skin thickness ranging from 7.6 mm to 14.3 mm.[@b14-ppa-4-379],[@b16-ppa-4-379] Therefore, a 12.7 mm depth of needle insertion with a skin-fold procedure should ensure that the injection of fluid is made into the SC tissue layer, regardless of the subject's body characteristics (including body mass index).

Subject pain with the self-injection system was lower than the values usually reported in studies using a 100 mm VAS, while pain following injection by a nurse was within the previously reported range.[@b7-ppa-4-379] Because pain is recognized as a factor impacting on subject compliance and injection anxiety, many clinical evaluations have investigated possible factors impacting on perceived pain. Needle sharpness and smaller needle diameter contribute significantly to reducing injection pain.[@b7-ppa-4-379] The autoinjector's automatic needle insertion into the skin might therefore contribute to minimizing perceived pain.[@b17-ppa-4-379] Considering the published data and the pain scores reported in the present study, pain was minimized by use of the autoinjector, which combines a prefilled syringe with a 12.7 mm, 27-gauge staked needle and automated needle insertion (8 mm exposed). Minimal pain was also reflected in the results of the verbal scale, which ranged from "hardly perceptible, without pain" to "perceptible, slightly painful".

Among other factors, slow speed of injection[@b18-ppa-4-379] and the injectable drug formulation (especially fluids that are particularly acidic or basic)[@b19-ppa-4-379] are reported as significantly influencing perceived pain. In a recent study in 40 healthy volunteers, pain associated with SC injection of a 0.9% saline solution was scored 14 ± 20 mm on a 100 mm VAS.[@b20-ppa-4-379] Half of the subjects experienced no pain on injection according to a six-item verbal scale. In another study in 84 healthy volunteers, the pain associated with SC injection of a saline solution was of similar magnitude (mean pain at injection 16.0 mm, 95% CI: 12.4%--19.7%).[@b21-ppa-4-379] An improvement in drug formulation may also contribute to minimizing perceived pain, and this has been demonstrated with the improved formulation of interferon beta 1b (Rebif^®^; Merck Serono SA, Geneva, Switzerland). It would therefore be of interest to evaluate pain at the injection site using the autoinjector in combination with the drug and in target patient populations.

Local skin reaction may also have a significant impact on patient compliance with chronic treatment with injectables. Local bleeding was more frequent with self-injections than with injections administered by nurses. However, in 63.8% of injections, bleeding was limited to "just a visible spot" at the injection site and, because the subjects did not spontaneously complain, it is unlikely that this would affect a patient's long-term acceptance of self-injections. Further investigation is warranted in clinical studies with injectable drugs, because bleeding might be influenced by the nature of the injected solution. All other items contributing to local skin reaction were comparable between the autoinjector and the syringe.

Hematomas were reported after injection in a few cases (15/960, 1.5%). The incidence of hematoma is infrequently reported in clinical studies, but the hematoma rate in the present study was considered comparable with that usually observed after SC injections of drugs other than anticoagulants. In a study of injections of placebo or erythropoietin, two hematomas at the injection site were recorded after 120 injections (1.7%).[@b22-ppa-4-379] In contrast, one study reported a 25% rate of hematoma after SC injection of low molecular weight heparin using a standard 26-gauge needle.[@b18-ppa-4-379]

Compliance with IFU for the self-injection system was evaluated at 93%, which was slightly, but significantly, higher among younger than older subjects. Regardless, an overall rate of over 90% compliance was considered good, considering that the subjects were initially naïve at performing self-injections (excluding initial study training). Subject adaptability to using the self-injection system was considered a good predictor of ease of use. Moreover, the positive attitudes of the subjects towards self-injections also reflected their acceptance of the autoinjector. Attitudes reflecting fear of pain generally lead to poor treatment compliance and avoidance behavior, while compliance may be improved by confidence building and reassurance.[@b23-ppa-4-379]

All 40 subjects selected self-injection at the end of the study, suggesting that the autoinjector is the preferred injection system. Subjects also selected self-injections using the autoinjector when asked which combination of operator and system they would prefer for weekly SC injections to control a chronic disease. The autoinjector handled by a nurse was ranked second, indicating that the autoinjector was preferred over the syringe, regardless of who is performing the injection. Preference for the autoinjector is probably a result of the system's features, such as low perceived pain, practicability, and ease of use. The results require further investigation in patients with chronic diseases and with injectable drugs, and relative to other autoinjectors with different features.

Conclusion
==========

In terms of technical performance, self-injection with the BD Physioject was not significantly different from injections using similar but "naked" syringes administered by nurses. There was no significant difference in the depth of the injection fluid depot between the two systems. Neither injection volume nor body site effected performance.

Self-injection with the BD Physioject was associated with greater acceptance, which was likely related to its self-injector features, including a low perception of pain, regardless of the site of administration (abdomen or thigh). Body site, gender, and injection volume did not affect perceived pain or acceptance.

A few skin reactivity events (mainly some visible spots and drops of blood at the injection site), and a few adverse events of mild intensity which spontaneously resolved at the end of the study were observed, and demonstrated good clinical tolerance and good local skin tolerance of the two systems.

The observed errorless handling of the autoinjector when giving self-injections, in compliance with the IFU, suggests that the system is convenient and easy to use.

In conclusion, this study demonstrated that self-injection with the BD Physioject is an efficient, safe, and intuitive procedure, very well accepted by subjects and preferred to an injection by a nurse. Improved treatment compliance may therefore be anticipated in patients with chronic disease requiring injectable treatment, based on the subjects' positive attitudes and spontaneously expressed preference for the autoinjector.
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![Study Design -- Each subject received a total of 24 injections in three sessions of 8 injections. With 40 subjects, a total of 960 injections were expected.](ppa-4-379f1){#f1-ppa-4-379}

![Box plots of depth of fluid depot in mm from skin surface after injection (ultrasound examination data). Description by device and volume for the per protocol population (mean, median, 25th and 75th percentiles, and range).\
**Note: \***Statistically outlying values.](ppa-4-379f2){#f2-ppa-4-379}

![Perceived pain, 100 mm visual analog scale (VAS; secondary endpoint) -- per protocol population.](ppa-4-379f3){#f3-ppa-4-379}

![Device acceptability score for four injection scenarios (mean and 95% confidence interval).\
**Notes:** At study end the subjects had to answer these four questions with a quotation from 1 ("Not at all probable") to 9 ("Completely probable"): "For a further chronic treatment administered by SC injection, I agree that I will perform myself these injections with an auto-injector?", I agree that I will perform myself these injections with a syringe?, I agree that a nurse will give me these injections with an auto-injector?, I agree that a nurse will give me these injections with a syringe?](ppa-4-379f4){#f4-ppa-4-379}

###### 

Screening and inclusion population

  -------------------------------------------------------------------------------------
  **Screened subjects**   **Included subjects**   **Age strata**     
  ----------------------- ----------------------- ------------------ ------------------
  N = 62                  N = 40                  12 male\           8 male\
                                                  8 female\          12 female\
                                                  Mean age (SD)\     Mean age (SD)\
                                                  28.8 (2.8) years   54.5 (5.8) years

  -------------------------------------------------------------------------------------

**Notes:** Nonincluded subjects, N = 22. Eight subjects removed their consent, seven subjects didn't satisfy eligibility criteria, and seven subjects were not included because age strata was already full when the center obtained all their screening results.

###### 

Fluid leakage and injected volume, gravimetric method (primary endpoint) -- per protocol population[a](#tfn3-ppa-4-379){ref-type="table-fn"}

  **Volume**                                                                **System**               **N**                                                                                  **Leakage (μL)**                                          **Injected volume (μL)**                       
  ------------------------------------------------------------------------- ------------------------ -------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------- ------------------- --------------
  0.2 ml                                                                    Self-injection/subject   205                                                                                    **1.7** (2.4)                                             **1.0** (1.0)              **206.8** (8.0)     **207** (4)
  Syringe/nurse                                                             233                      **2.1** (2.6)                                                                          **1.0** (1.0)                                             **206.6** (5.8)            **208** (2)         
  1 ml                                                                      Self-injection/subject   206                                                                                    **3.3** (17.5)[c](#tfn5-ppa-4-379){ref-type="table-fn"}   **1.0** (1.0)              **1013.0** (19.9)   **1015** (4)
  Syringe/nurse                                                             227                      **1.6** (2.0)                                                                          **1.0** (1.0)                                             **1012.0** (7.1)           **1013** (3)        
  Total of analyzed injections                                              **871**                                                                                                                                                                                                                  
                                                                            Missing data             1 missing value for an injection by a nurse[b](#tfn4-ppa-4-379){ref-type="table-fn"}                                                                                                            
  88 leakages were not collected[d](#tfn6-ppa-4-379){ref-type="table-fn"}                                                                                                                                                                                                                            
  Total of performed injections                                             **960**                                                                                                                                                                                                                  

**Notes:**

the per protocol population is the study population used for the main criteria analysis (excluding the 88 cases without leakage collection);

one missing value for an injection into the abdomen by a health care professional;

this mean (SD) is inflated by an outlying value of 223μL (the mean \[SD\] without this outlying value is 2.2 μL \[8.5 μL\]);

When the leakage was not collected it was impossible to calculate the injected volume. Cases without leakage collected (n = 88) were excluded from main criteria analysis;

Median Absolute deviation.

###### 

Perceived pain, 100 mm visual analog scale (VAS) and verbal scale (VS) -- per protocol population

  **PP set**                                             **Device**      **Volume**      **Device**                                                    **Site**                                                      **Gender**                                                                                                                                        
  ------------------------------------------------------ --------------- --------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  N[a](#tfn9-ppa-4-379){ref-type="table-fn"}             480             480             480                                                           480                                                           240                                                           240           240           240           481           479           480           480
  Pain VAS[b](#tfn10-ppa-4-379){ref-type="table-fn"}:                                                                                                                                                                                                                                                                                                                  
  Mean (SD)                                              6.6 (9.6)       15.2 (16.6)     9.2 (13.5)                                                    12.6 (14.7)                                                   4.6 (7.3)                                                     8.5 (11.1)    13.8 (16.5)   16.7 (16.5)   10.6 (13.8)   11.1 (14.6)   13.1 (15.3)   8.7 (12.6)
  *P*-values[c](#tfn11-ppa-4-379){ref-type="table-fn"}   *P* \< 0.0001   *P* = 0.0003    *P* = 0.5738 (NS)[d](#tfn12-ppa-4-379){ref-type="table-fn"}   *P* = 0.6143 (NS)[d](#tfn12-ppa-4-379){ref-type="table-fn"}   *P* \< 0.0001                                                                                                                                     
  Pain VS[b](#tfn10-ppa-4-379){ref-type="table-fn"}:                                                                                                                                                                                                                                                                                                                   
  Mean (SD)                                              12.1 (9.8)      22.3 (14.0)     14.7 (12.1)                                                   19.6 (13.6)                                                   9.4 (7.8)                                                     14.7 (10.9)   20.0 (13.4)   24.6 (14.2)   17.1 (12.9)   17.2 (13.3)   17.4 (12.2)   16.9 (14.0)
  *P*-values[c](#tfn11-ppa-4-379){ref-type="table-fn"}   *P* \< 0.0001   *P* \< 0.0001   *P* = 0.6408 (NS)[d](#tfn12-ppa-4-379){ref-type="table-fn"}   *P* = 0.9034 (NS)[d](#tfn12-ppa-4-379){ref-type="table-fn"}   *P* = 0.7846 (NS)[d](#tfn12-ppa-4-379){ref-type="table-fn"}                                                                                       

**Notes:**

no missing data;

in mm;

*P*-values from mixed model;

NS = not statistically significant.

###### 

Local skin reactions at injection site -- Safety population[a](#tfn14-ppa-4-379){ref-type="table-fn"}

                                                             **Auto-injector/subject**   **Syringe/nurse**   
  ---------------------------------------------------------- --------------------------- ------------------- -----------------------------------------------------------
  Bleeding[b](#tfn15-ppa-4-379){ref-type="table-fn"} N (%)   207 (43.1)                  51 (10.6)           *P* \< 0.0001[c](#tfn16-ppa-4-379){ref-type="table-fn"}
  Edema N (%)                                                16 (3.3)                    92 (19.2)           *P* \< 0.0001[c](#tfn16-ppa-4-379){ref-type="table-fn"}
  Bruising N (%)                                             3 (0.6)                     1 (0.2)             Not significant[d](#tfn17-ppa-4-379){ref-type="table-fn"}
  Itching N (%)                                              1 (0.2)                     0 (0.0)             Not significant[d](#tfn17-ppa-4-379){ref-type="table-fn"}
  Erythema N (%)                                             6 (1.3)                     5 (1.1)             Not significant[d](#tfn17-ppa-4-379){ref-type="table-fn"}

**Notes:**

the safety population includes all subjects with at least one injection;

132/207 (63.8%) for Auto-injector/Subject and 30/51 (58.8%) for Syringe/Nurse are categorized as "just a spot";

from ordinal logistic regression;

Fisher's exact test.
